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PTP-PEST (encoded by Ptpn12) is an intracellu-
lar protein tyrosine phosphatase belonging to the
same family as LYP. LYP inhibits secondary T cell
responses by suppressing Src family protein tyrosine
kinases and is implicated in human autoimmunity.
To determine the function of PTP-PEST in T cells,
we generated mice with a conditionally deleted allele
of Ptpn12. By removing PTP-PEST in T cells, we
determined that PTP-PEST was not necessary for
T cell development or primary responses. How-
ever, PTP-PEST was required for secondary T cell
responses, anergy prevention, and autoimmunity
induction. PTP-PEST specifically regulated the phos-
phorylation of Pyk2, a substrate of the Src fam-
ily kinase Fyn. It also promoted the formation of
T cell homoaggregates, which are known to enhance
T cell activation. Thus, PTP-PEST controls Pyk2
activity and is a positive regulator of secondary
T cell activation. These data illustrate the critical
role of protein tyrosine phosphatases in T cell
regulation.
INTRODUCTION
The proline-, glutamic acid-, serine-, and threonine-rich (PEST)
family of intracellular protein tyrosine phosphatases (PTPs)
includes PTP-PEST (PTPN12), lymphoid tyrosine phosphatase
(LYP) (also known as proline-enriched phosphatase [PEP] or
PTPN22; hereafter named LYP) and PTP-hematopoietic stem
cell fraction (HSCF) (Veillette et al., 2002; Veillette et al., 2009;
Bottini et al., 2006). These enzymes are composed of an
amino-terminal PTP domain, a central protein-protein interaction
domain, and a conserved carboxyl-terminal tail. LYP and PTP-
HSCF are expressed in hematopoietic cells, whereas PTP-
PEST is expressed in all cell types, albeit in the highest amounts
in immune cells.
In immune cells, the best-characterized PEST family member
is LYP. LYP is a negative regulator of T cell activation (Cloutierand Veillette, 1999; Cloutier and Veillette, 1996; Hasegawa
et al., 2004). This activity correlates with the ability of LYP to
dephosphorylate and inactivate Src family protein tyrosine
kinases (PTKs) (Lck and Fyn) and ZAP-70, which initiate T cell
activation. T cells from LYP-deficient mice are hyperresponsive
to T cell receptor (TCR) stimulation (Zikherman et al., 2009;
Hasegawa et al., 2004). Intriguingly, this effect is seen in previ-
ously activated T cells, but not in naive T cells (Hasegawa
et al., 2004). LYP-deficient mice also exhibit an accumulation
of effector-memory T cells, an expansion of germinal centers
and an increase in antibody amounts. Thus, LYP inhibits T cell
activation only in effector-memory T cells. A point mutation in
human LYP that affects the ability to regulate TCR signaling is
a risk factor for autoimmune diseases like type 1 diabetes, lupus,
and rheumatoid arthritis (Bottini et al., 2006; Bottini et al., 2004).
The roles of the other PEST family members in immune cells
are not well understood. In nonimmune cells, PTP-PEST can
dephosphorylate the cytoskeleton-associated adaptors Cas,
PSTPIP-1, and paxillin and the focal adhesion-associated
PTKs FAK and Pyk2 (Badour et al., 2004; Davidson and Veillette,
2001; Garton and Tonks, 1999; Cote´ et al., 1998; Shen et al.,
1998; Garton et al., 1996; Cong et al., 2000). It can also regulate
cell adhesion, spreading, and migration. Overexpression anal-
yses in lymphoid cells suggested that PTP-PEST may also be
an inhibitor of lymphocyte activation (Badour et al., 2004; David-
son and Veillette, 2001; Arimura et al., 2008). This activity was
linked to the ability of PTP-PEST to dephosphorylate Src
kinases, FAK, Pyk2, Shc, or WASP. Thus, like LYP (Zikherman
et al., 2009; Hasegawa et al., 2004), PTP-PESTmaybe a negative
regulator of T cell activation. However, the physiological rele-
vance of this effect has not been confirmed because conven-
tional PTP-PEST-deficient mice exhibit an early embryonic
lethality (Sirois et al., 2006).
To address the physiological role of PTP-PEST in T cells, we
generated a mouse having a conditionally targeted allele of
Ptpn12, the gene encoding PTP-PEST. By crossing this mouse
with mice expressing the Cre recombinase in T cells, we found
that PTP-PEST was not necessary for T cell development and
primary T cell responses. However, it was required for secondary
T cell activation, inhibition of anergy, and induction of autoimmu-
nity. These activities correlated with the selective capacity of
PTP-PEST to dephosphorylate Pyk2, a substrate of Fyn, and to
enhance the formation of homoaggregates between T cells.Immunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc. 167
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Figure 1. Primary T Cell Responses in PTP-
PEST-Deficient Mice
(A) PurifiedCD4+ T cells were activated in vitro with
the indicated stimuli. After 48 hr, proliferation
and cytokine production were determined by
measuring thymidine incorporation and by ELISA,
respectively. Standard deviations of triplicate
values are shown. CPM, counts per min; aCD3,
anti-CD3; aCD28, anti-CD28; P+I, PMA plus iono-
mycin. A representative of seven experiments is
shown.
(B and C) Purified CD4+ T cells from the indicated
mice, expressing the (B) pidgeon cytochrome C
(PCC)-specific transgenic TCR AND or (C) the
ovalbumin (OVA)-specific transgenic TCR OT-II,
were activated with antigenic peptides and sple-
nocytes, or with P+I. Activation was monitored as
detailed in (A). Standard deviations of triplicate
values are shown. A representative of five experi-
ments (B) or one experiment (C) is shown.
(D) Mice (n = 4–6 in each group) were immunized
with trinitrophenyl (TNP)-chicken gamma globulin
(CGG) plus alum. After 14 days, TNP-specific
serum immunoglobulins (Ig) were measured by
ELISA. Symbols represent individual mice. Aver-
age values are shown as horizontal bars. Similar
results were observed when antibody levels were
assessed 7 or 21 days after immunization (data
not shown). In all cases, p values were nonsignifi-
cant (>0.05). A representative of two experiments
encompassing ten conditional PTP-PEST-defi-
cient mice is shown. See also Figure S1 and
Table S1.
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PTP-PEST Regulates Secondary T Cell ResponsesRESULTS
PTP-PEST Is Not Necessary for Primary CD4+ T Cell
Responses
We engineered a mouse with a conditional allele of the gene
encoding PTP-PEST (Ptpn12) (see Supplemental Experimental
Procedures and Figure S1 available online). To determine the
role of PTP-PEST in T cells, we bred Ptpn12fl/fl mice with mice
expressing the Cre recombinase under the control of the Lck
or Cd4 promoter. Mice expressing Cre alone or carrying the
floxed allele alone were used as ‘‘wild-type’’ controls. Unless
specified, the experiments shown used Ptpn12+/+Cre+ mice as
controls. Cre-mediated deletion of the floxed alleles resulted
in a >95% reduction of the abundance of PTP-PEST in T cells168 Immunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc.a
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observed (data not shown). PTP-PEST
deficiency had no effect on T cell num-
bers or subpopulations, the numbers
or proportions of naive, effector-memory,
and CD4+Foxp3+ regulatory T (Treg) cells,
and the proportions of natural killer (NK)-T
cells (Table S1; data not shown).
To examine the impact of PTP-PEST on
T cell activation, we focused our studies
on CD4+ T cells. Freshly purified con-
trol and PTP-PEST-deficient (hereafter
named Ptpn12/) CD4+ T cells were
ctivated in vitro with anti-CD3, without or with anti-CD28.
TP-PEST deficiency had no effect or only a small stimulatory
ffect (<1.5-fold) on thymidine incorporation and production of
terferon (IFN)-g, interleukin (IL)-2, IL-4 and IL-17 (Figure 1A).
TP-PEST-deficient mice were also crossed with class II major
istocompatibility complex (MHC)-restricted TCR transgenic
ice AND and OT-II (Kaye et al., 1989; Barnden et al., 1998).
ompared to CD4+ T cells from control TCR transgenic mice,
tpn12/ T cells showed little or no alteration in thymidine
corporation and cytokine production in response to antigenic
eptides plus splenocytes (Figures 1B and 1C).
We also examined primary CD4+ T cell responses in vivo by
munizing mice with trinitrophenyl (TNP)-chicken gamma glob-
lin (CGG) and alum and measuring antibodies against the
Immunity
PTP-PEST Regulates Secondary T Cell Responseshapten TNP (Figure 1D). Production of TNP antibodies is depen-
dent on proper CD4+ T cell helper functions. Lack of PTP-PEST
in T cells had no effect on the ability to produce TNP antibodies.
Similar results were obtained when mice were immunized with
ovalbumin (OVA) or a myelin oligodendrocyte glycoprotein
(MOG) peptide (see below). Thus, PTP-PEST deficiency had little
or no effect on T cell development and differentiation and on
primary CD4+ T cell responses.
PTP-PEST Is a Positive Regulator of Secondary CD4+
T Cell Activation
The impact of PTP-PEST deficiency on secondary CD4+ T cell
responses was evaluated (Figure 2). CD4+ TCR AND T cells
were first activated with anti-CD3 plus anti-CD28 and subse-
quently restimulated in vitro with antigen and antigen-presenting
cells (APCs) (Figure 2A). In comparison to control T cells, previ-
ously activated Ptpn12/ T cells exhibited a decrease in thymi-
dine incorporation (to 50%) and cytokine production (to
10%–20%) upon restimulation. The latter was true for IFN-g,
IL-2, and IL-4. This was surprising, given that earlier overexpres-
sion studies had suggested that PTP-PEST is a negative regulator
of T cell activation (Badour et al., 2004; Davidson and Veillette,
2001; Arimura et al., 2008). No effect on production of the immu-
nosuppressive cytokine IL-10 and transforming growth factor
(TGF)-b was seen (Figure S2A). Similar results were obtained
when the reverse stimulation protocol was used, in which CD4+
TCR AND T cells were first activated with antigen and APCs,
and then restimulated with anti-TCR plus anti-CD28 or anti-CD3
plus anti-CD28 (Figure S2B; data not shown). A decreased rate
of cell division was also noted when cells were labeled with car-
boxyfluorescein succinimidyl ester (CFSE) (FigureS2C). Likewise,
a delay in cell cycle progression was observed when permeabi-
lized cells were stained with propidium iodide (PI) (Figure S2D).
These various defects were not due to a loss of transgenic TCR
expression (data not shown) nor to an increase in activation-
induced cell death (Figure S2E). Furthermore, they did not reflect
a global defect in responsiveness, as cells responded normally
to phorbol myristate acetate (PMA) plus ionomycin (P+I).
Next, we tested secondary T cell responses by using antigen-
specific T cells generated in vivo (Figure 2B). Mice (devoid of
transgenic TCR) were injected with OVA and adjuvant. After
9 days, draining lymph node CD4+ T cells were restimulated
in vitro with OVA and splenocytes. Ptpn12/ T cells demon-
strated a marked decrease (to 10%–20%) in thymidine incor-
poration, as well as in secretion of IFN-g and IL-2. These defects
did not relate to a lack of primary CD4+ T cell response in vivo,
as judged by staining of lymph node cells with class II MHC
tetramers loaded with an OVA peptide or by short-term restimu-
lation with P+I, followed by intracellular staining for IFN-g
(Figure 2C; Figure S2F). Effector-memory T cells, but not naive
T cells, undergo rapid production of IFN-g after short-term
restimulation with P+I (Hatton et al., 2006). Moreover, there
was no defect in the appearance of OVA antibodies (Figure S2G).
To explain these findings, we examined whether PTP-PEST
deficiency might be enhancing the number or activity of Treg
cells (Figure 2D). There was no greater number of CD4+Foxp3+
Treg cells in lymph nodes of OVA-immunized PTP-PEST-
deficient mice, compared to OVA-immunized control mice.
Moreover, in in vitro suppression assays, CD4+ T cells fromOVA-immunized PTP-PEST-deficient mice failed to suppress
thymidine incorporation and cytokine production of CD4+
T cells from OVA-immunized control mice (Figure 2E). In fact,
the defect in thymidine incorporation of Ptpn12/ T cells
appeared to be corrected when they were added to cells from
control mice. This rescue could be caused by the ability of
control T cells to secrete growth-stimulating cytokines such as
IL-2 or to promote contacts between T cells (see below). There-
fore, PTP-PEST was intrinsically required for the ability of T cells
to respond to secondary stimulation.
Selective Deregulation of Pyk2 and Rac1
in Ptpn12/ T Cells
To understand the mechanism by which PTP-PEST enhanced
secondary T cell responses, we examined the effect of PTP-
PEST deficiency on TCR-triggered signals (Figure 3). T cells
were stimulated or not with anti-CD3 alone or plus anti-CD28,
and protein tyrosine phosphorylation was monitored (Figure 3A).
PTP-PEST deficiency had no effect on tyrosine phosphorylation
of most substrates in resting or TCR-stimulated T cells. The only
exception was a 115 kilodalton (kDa) protein, which exhibited
enhanced tyrosine phosphorylation in Ptpn12/ T cells.
This was seen in fresh ex vivo and previously activated T cells,
as well as in resting and, to a lesser extent, TCR-stimulated
T cells. Immunoblotting with phospho-Pyk2-specific antibodies
suggested that p115 was Pyk2, a member of the FAK family
of PTKs that is highly expressed in hematopoietic cells and
undergoes tyrosine phosphorylation by Fyn upon TCR stimula-
tion (Ostergaard et al., 1998; Qian et al., 1997). This notion was
confirmed both by immunoprecipitation and by depletion exper-
iments using anti-Pyk2 (Figure 3B; Figure S3A). Pyk2 was likely
a direct substrate of PTP-PEST, given that recombinant PTP-
PEST was apt at dephosphorylating Pyk2 in vitro (Figure S3B).
PTP-PEST deficiency had little or no effect on tyrosine phos-
phorylation of other known PTP-PEST substrates such as FAK,
CasL, Cas, PSTPIP-1 and Shc (Figure 3B). It also did not interfere
with TCR-triggered activation of the kinases Erk, JNK, p38,
and Akt and protein kinase C (PKC)-q and IkBa activation and
degradation (Figure 3C). Similar results were obtained with
CD4+ TCR AND T cells previously activated with antigen-MHC
(Figure S3C). Likewise, lack of PTP-PEST had no effect on
capping of the TCR complex or actin polymerization (Figures
S3D and S3E). Nonetheless, it resulted in a modest, albeit repro-
ducible, decrease in Ca2+ mobilization (Figure 3D). More notice-
ably, it led to an increase in basal activity of the small guanine
nucleotide-binding protein Rac1 (a known effector of Pyk2
[Gismondi et al., 2003]) and, paradoxically, a decrease in TCR-
induced activation of Rac1 (Figure 3E). The impact of PTP-
PEST deficiency on baseline Pyk2 tyrosine phosphorylation
was not corrected by P+I (Figure S3F), arguing that P+I was
rescuing functional responses (Figure 2) by acting downstream
of Pyk2. Hence, PTP-PEST deficiency caused a selective
increase in Pyk2 tyrosine phosphorylation, which was accompa-
nied by deregulation of Rac1.
Compromised Homoaggregate Formation
by Ptpn12/ T Cells
PTP-PEST, like Pyk2 and Rac1, regulates cell adhesion, at least
in nonlymphoid cells (Veillette et al., 2009; Larsen et al., 2003;Immunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc. 169
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Figure 2. Severely Compromised Secondary T Cell Responses in PTP-PEST-Deficient Mice
(A) Purified CD4+ T cells from TCR AND transgenic mice were first activated in vitro with anti-CD3 plus anti-CD28. They were then restimulated with PCC peptide
and irradiated splenocytes, or with PMA plus ionomycin (P+I). Thymidine incorporation and cytokine production weremonitored. Standard deviations of triplicate
values are shown. A representative of eight experiments is shown.
(B–D) Mice (two representative mice from each group) were immunized with OVA and complete Freund adjuvant in the foot pad. As shown in (B), after 9 days,
CD4+ T cells were isolated from popliteal lymph nodes and restimulated with OVA and splenocytes, or P+I. After 4–5 days (for OVA restimulation) or 2 days (for P+I
stimulation), activation was monitored as detailed in (A). Standard deviations of triplicate values are shown. As shown in (C), CD4+ T cells from draining lymph
nodes of immunized mice were stained with class II MHC-tetramers loaded with OVA323-339 peptide and analyzed by flow cytometry. As the control, cells were
stained with tetramers loaded with an irrelevant peptide. The total numbers of tetramer-positive cells in draining lymph nodes are shown. As shown in (D), the
relative abundance of CD4+Foxp3+ T cells in draining lymph nodes was assessed by flow cytometry. A representative of eight (B), three (C), and two (D) exper-
iments is shown.
(E) Suppressor activity in draining lymph nodes was assessed by mixing CD4+ T cells from control mice with CD4+ T cells from PTP-PEST-deficient mice (at the
indicated ratios), prior to in vitro restimulation with OVA, as described in (B). A representative of two experiments is shown. See also Figure S2.
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PTP-PEST Regulates Secondary T Cell ResponsesBishop and Hall, 2000; Avraham et al., 2000). Therefore,
we tested whether PTP-PEST might be affecting the ability of
T cells to contact APCs (Figure S4A). Lack of PTP-PEST had170 Immunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc.no influence on the ability of previously activated CD4+ T cells
to form conjugates with B cells. This was seen over a range
of antigen concentrations and at several times after antigen
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(A) Freshly purified (left) or previously activated (right) CD4+ T cells were stimulated with anti-CD3 for 2 min on the left or for the indicated times on the right.
Phosphotyrosine (P.tyr)-containing proteins were detected by immunoblotting of total cell lysates with anti (a)-P.tyr. The position of a 115 kilodalton-protein
(p115) showing selective hyperphosphorylation in Ptpn12/ T cells is shown on the left. Phosphorylated Pyk2, total Pyk2, and PTP-PEST were also detected
by immunoblotting with phospho-specific anti-Pyk2, anti-Pyk2, or anti-PTP-PEST (PEST), respectively. A representative of two (left) or at least ten (right) exper-
iments is shown.
(B–E) Signaling in previously activated CD4+ T cells. As shown in (B), cells were stimulated or not for 2 min with anti-CD3. Polypeptides were recovered by immu-
noprecipitation and probed by immunoblotting with anti-P.tyr or the specified antibodies. Quantitation of phosphorylated Pyk2 relative to that of the unstimulated
control is shown. NRS, normal rabbit serum. A representative of at least five (Pyk2) or two (other substrates) experiments is shown. As shown in (C), cells were
stimulated with anti-CD3 or anti-CD3 plus anti-CD28. Activation of Erk, Akt, p38, JNK, PKC-q, and IkBa was determined by immunoblotting with phospho-
specific antibodies. A representative of one to three experiments, depending on the panel, is shown. As shown in (D), cells were loadedwith Indo-1 and stimulated
with anti-CD3 (left) or ionomycin (Iono; right). Changes in intracellular Ca2+ were determined by ascertaining the fluorescence (FL) 4 to FL5 ratio (FL4/FL5), with
a BD LSR flow cytometer. An arrow (bottom) indicates when the stimulus was added. A representative of four experiments is shown. As shown in (E), cells were
stimulated or not for the indicated periods of time with anti-CD3. Rac1 activity was determined with a Rac1 activation assay kit. Rac1 activity is represented as
arbitrary units. Standard deviations of triplicates are shown. Expression of Rac1 was analyzed by Rac1 immunoblotting (insert). A representative of four exper-
iments is shown. See also Figure S3.
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PTP-PEST Regulates Secondary T Cell Responsesstimulation. In contrast, the capacity of Ptpn12/ T cells to form
large T cell aggregates upon antigen-MHC restimulation was
severely compromised (Figure 4A; Figure S4B). This was trueat all times after restimulation. No difference was observed
when cells were stimulated with P+I. Activation-induced aggre-
gates are a hallmark of T cell activation. They are formed byImmunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc. 171
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Figure 4. Reduced Homoaggregate Formation by Ptpn12/ T Cells
(A) CD4+ T cells from TCR AND transgenic mice were first activated with anti-CD3 plus anti-CD28. They were then restimulated or not with PCC peptide (1 mM)
plus splenocytes or with PMA plus ionomycin (P+I). The formation of cell aggregates was assessed by light microscopy. Cell clusters larger than 83 103 mm2
(for control or peptide stimulation) or 23 103 mm2 (for P+I stimulation) were quantitated by counting representative visual fields of 5 mm2. Representative time
points are shown. A more detailed representation of the data is depicted in Figure S4B. Standard deviations of triplicates are shown. A representative of five
experiments is shown.
(B) Cells were stimulated for 24 hr and analyzed as detailed in (A), except that IL-2 (100 U/ml) was added or not during restimulation with antigen-MHC. Thymidine
incorporation and IFN-g secretion were also monitored (right). Standard deviations of triplicate values are shown.
(C and D) This experiment was conducted as detailed in (A), except that control cells (labeled with CFSE) and Ptpn12/ T cells (labeled with CMTMR) were stim-
ulated alone (403 104 cells) or in mixed cultures (20 3 104 cells each). A representative of two experiments is shown. As shown in (C), aggregate formation was
examined by fluorescencemicroscopy (top). Inmixed cultures, the percentage of clusters containing control cells alone,Ptpn12/ T cells alone or both cell types
was quantitated (bottom). A representative of three experiments is shown. As shown in (D), thymidine incorporation and IFN-g production were monitored. As
shown in the middle panel, total IFN-g production was studied by ELISA. As shown in the right panel, IFN-g production was analyzed by intracellular staining;
production of IFN-g was calculated by multiplying the mean fluorescence intensity (mfi) of IFN-g+ cells by the percentage of IFN-g+ for each cell type in pure or
mixed cultures. Standard deviations of triplicates are shown. A representative of two experiments is shown.
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Immunity
PTP-PEST Regulates Secondary T Cell ResponsesT cell homoconjugates and are believed to strengthen T cell acti-
vation by favoring exchanges of cytokines, in particular IL-2,
between T cells (Sabatos et al., 2008).
To assess whether the decreased aggregate formation was
simply due to reduced IL-2 production, we conducted similar
experiments in the presence of exogenous IL-2 (Figure 4B). IL-2
only minimally improved aggregate formation by Ptpn12/
T cells, implying that the decreased aggregation was not due
to reduced IL-2 secretion. However, addition of IL-2 corrected
the thymidine incorporation and IFN-g secretion defects seen
in Ptpn12/ T cells, implying that the stimulatory role of aggre-
gate formation during T cell activation might be bypassed by
supplying exogenous IL-2.
To test more directly the contribution of reduced homoaggre-
gate formation to the compromised activation of Ptpn12/
T cells, we studied the ability to rescue the defects of Ptpn12/
T cells by mixing these cells with control T cells (Figures 4C and
4D). Using cells differentially labeled with CFSE or 5-(and-6)-
(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine (CMTMR),
we found that control T cells rescued aggregate formation by
Ptpn12/ T cells (Figure 4C). Considering that the number
of control cells in mixed cultures was only half of that in pure
cultures, control cells also seemed to correct the thymidine
incorporation and IFN-g secretion defects seen in Ptpn12/
T cells (Figure 4D). To ensure that the latter was the case,
single-cell analyses of IFN-g secretion were also performed
with intracellular staining. Compared to pure aggregates, the
extents of IFN-g production by control and Ptpn12/ T cells in
mixed aggregates were equivalent.
The integrin leukocyte-function-antigen-1 (LFA-1) and its
ligand, intercellular adhesion molecule-1 (ICAM-1), are both
expressed on activated T cells and play a critical role in
T cell-T cell interactions (Sabatos et al., 2008). Consequently,
we examined the impact of PTP-PEST deficiency on the expres-
sion and function of these two molecules. PTP-PEST deficiency
had no impact on the amounts of LFA-1 and ICAM-1 on activated
T cells (Figure S4C). However, it caused a reproducible decrease
in the ability of T cells to bind soluble ICAM-1 in response to
antigen-MHC, presumably reflecting a decrease in the affinity
or avidity of LFA-1 (Figure 4E). This was not the case when cells
were stimulated with PMA or when ICAM-1 was immobilized on
plastic (Figure 4E; Figure S4D). Immobilization of ICAM-1 on
plastic can mask differences in LFA-1 affinity (Kinashi, 2005).
Although the magnitude of the changes in soluble ICAM-1
binding may seem small, it was similar to those reported by
other groups (Stewart et al., 1996; Baker et al., 2009). Finally,
we examined the ability of LFA-1 to mediate intracellular bio-
chemical signals (Figure S4E). Lack of PTP-PEST had no impact
on the aptitude of LFA-1 to enhance overall protein tyrosine
phosphorylation, Pyk2 tyrosine phosphorylation, and Erk
activation, although it augmented baseline Pyk2 tyrosine phos-
phorylation.
Thus, Ptpn12/ T cells exhibited a strong decrease in T cell
homoaggregation, but not in conjugate formation with APCs.
This defect correlated with decreased binding of LFA-1 to(E) Previously activated CD4+ T cells were stimulated or not for 30 min, stained
control antibody (human IgG1) was used as control. The difference in mean fluores
Standard deviations of triplicates are shown. A representative of two experimensoluble ICAM-1, presumably reflecting a reduction of the affinity
or avidity of LFA-1. No change in LFA-1 expression or signaling
capabilities was seen. Enforced homoaggregate formation or
the presence of exogenous IL-2 was able to rescue the activa-
tion defects seen in Ptpn12/ T cells, suggesting that compro-
mised homoaggregate formation and reduced IL-2 exchanges
between aggregated T cells contributed to the diminished
responsiveness of Ptpn12/ T cells.
PTP-PEST Inhibits the Induction of Anergy-like States
A decrease in responsiveness of previously activated T cells is
also seen in T cell anergy, a state of hyporesponsiveness typi-
cally produced when initial TCR engagement occurs without
adequate costimulation (Choi and Schwartz, 2007). To ascertain
whether PTP-PEST influenced sensitivity to anergy-like states,
we used two in vitro models: anti-CD3-induced anergy and ion-
omycin-induced anergy (Figure 5) (Jenkins et al., 1990; Macian
et al., 2002). CD4+ T cells were first activated with anti-CD3
plus anti-CD28 and, later, treated or not with anti-CD3 or iono-
mycin to induce anergy. T cells were then restimulated with
anti-CD3 plus anti-CD28 and assayed for thymidine incorpora-
tion and IL-2 production. As expected, treatment of control
T cells with anti-CD3 (Figure 5A) inhibited subsequent thymidine
incorporation and IL-2 production. The ‘‘anergy index,’’ defined
as the ratio of thymidine incorporation between cells treated
with medium and cells exposed to the anergizing regimen, was
3.1. A smaller, albeit reproducible, anergizing effect (index of
1.3) was seen when control cells were treated with ionomycin
(Figure 5B). In Ptpn12/ T cells, these indices were increased
to 57.1 (18-fold increase) and 4.0 (3-fold increase) for anti-
CD3- or ionomycin-induced anergy, respectively. Similar effects
were seen when IL-2 secretion was measured. As reported in
other settings (Choi and Schwartz, 2007), anergy was largely
rescued by exogenous IL-2 (Figure 5C).
We also studied the sensitivity of PTP-PEST-deficient mice to
anergy in vivo (Figure 5D) (Mittrucker et al., 1996). Mice were
injected with the superantigen staphylococcal enterotoxin B
(SEB) or phosphate-buffered saline (PBS). After 10 days, CD4+
T cells were restimulated with SEB, and assayed for thymidine
incorporation and IL-2 secretion. Control and PTP-PEST-defi-
cient mice showed no difference in the abundance of Vb8.1/
8.2+ CD4+ T cells, which mediate responsiveness to SEB (see
the legend of Figure 5). Treatment of control mice with SEB
caused an inhibition of thymidine incorporation and IL-2 secre-
tion upon SEB restimulation, in keeping with anergy induction.
In PTP-PEST-deficient mice, anergy induction was much
stronger. This effect was seen at all concentrations of SEB
used for restimulation.
To determine the signaling defects responsible for the
enhanced sensitivity of PTP-PEST-deficient mice to anergy-
like states, we performed biochemical analyses analogous to
those described in Figure 3 (Figure S5). The only observed alter-
ation was an increased Pyk2 tyrosine phosphorylation, both in
resting and in anergized T cells (Figure S5A). There was no effect
on the extent of nuclear factor of activated T cells (NFAT) andwith soluble ICAM-1 and assayed by flow cytometry. Staining with an isotype
cence between stimulated and resting cells (D binding) is depicted on the right.
ts is shown. See also Figure S4.
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Figure 5. Enhanced Susceptibility to T Cell Anergy-like States in PTP-PEST-Deficient Mice
(A–C) CD4+ T cells from the indicated mice were activated with anti-CD3 plus anti-CD28, and subsequently expanded in medium containing IL-2. They were then
treated or not with anti-CD3 (1 mg/ml) (A) or ionomycin (Iono; 1 mM) (B) and restimulated with anti-CD3 and anti-CD28. In (C), recombinant IL-2 (100 U/ml) was
added during the final restimulation. Proliferation was determined by thymidine incorporation, and IL-2 secretion was assessed by ELISA. The anergy index is the
ratio of thymidine incorporation or IL-2 secretion between untreated and anti-CD3- or ionomycin-treated cells. Standard deviations of triplicates are shown.
A representative of three experiments is shown.
(D) Mice were injected i.p. with Staphylococcus aureus enterotoxin B (SEB; 100 mg) or PBS alone. After 10 days, splenic CD4+ T cells were isolated and incubated
for 4.5 days with SEB (0.37–10 mg/ml) and splenocytes. Thymidine incorporation and IL-2 secretion were monitored. The anergy index is the ratio of thymidine
incorporation or IL-2 secretion between PBS-injected and SEB-injected mice. The anergy indices for restimulation with 3.3 mg/ml of SEB are shown on the left.
Standard deviations of triplicate values are depicted. The values for all SEB concentrations are represented on the right. The proportions of Vb8.1/8.2+ cells in
CD4+ T cells were: PBS-treatedmice: control, 16.0%;Ptpn12/, 17.2%; SEB-treated: control, 11.5%;Ptpn12/, 11.4%. A representative of four experiments is
shown. See also Figure S5.
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PTP-PEST Regulates Secondary T Cell Responsesactivator protein-1 (AP-1) activation during anergy induction
(Figure S5B). Consequently, PTP-PEST was inhibiting the induc-
tion of anergy-like states in T cells, and this effect specifically
correlated with dephosphorylation of Pyk2.
Suppression of Pyk2 Reduces Anergy-like States
The selective hyperphosphorylation of Pyk2 in Ptpn12/ T cells
suggested that deregulation of Pyk2 was altering their respon-
siveness. To test this idea, we examined the impact of sup-
pressing Pyk2 function on T cell anergy, utilizing three comple-
mentary approaches (Figure 6; Figure S6). First, we examined
the effect of downregulating Pyk2 expression by using small
interfering (si) RNAs (Figures 6A and 6B). T cells were infected
with retroviruses encoding Pyk2-specific or nonspecific siRNAs.
Cells expressing Pyk2-specific siRNAs exhibited a partial down-174 Immunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc.regulation of Pyk2 expression (Figure 6A). Furthermore, they
had a reduced sensitivity to anti-CD3-induced anergy
(Figure 6B). This was true both for control T cells and for
Ptpn12/ T cells.
Second, we used a pharmacological inhibitor of Pyk2,
PF-562,271 (Figures S6A and S6B) (Bagi et al., 2008; Roberts
et al., 2008). This compound efficiently inhibits Pyk2 and FAK,
but not Fyn and Lck. Because we detected very little if any tyro-
sine phosphorylation of FAK in our studies, we assumed that
the effect of the inhibitor was not mediated by FAK. PF-
562,271 suppressed tyrosine phosphorylation of Pyk2, but not
overall protein tyrosine phosphorylation, in resting and acti-
vated T cells (Figure S6A). Moreover, it prevented the ability
of anti-CD3 to induce anergy, both in control T cells and in
Ptpn12/ T cells (Figure S6B). It is possible that the stronger
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(A and B) Previously activated CD4+ T cells were infected with retroviruses encoding green fluorescent protein (GFP) and Pyk2-specific or irrelevant (‘‘Scram-
bled’’) small interfering (si) RNAs. After sorting GFP+ cells, cells were analyzed by immunoblotting with anti-Pyk2 (A) or for anti-CD3-induced anergy as detailed
for Figure 5 (B).
(C andD) Previously activated CD4+ T cells from the indicatedmicewere stimulated or not for 2.5min with anti-CD3 and various signals were tested as detailed for
Figure 3 (C). They were also analyzed for anti-CD3-induced anergy (D). All panels are representative of two experiments. See also Figure S6.
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PTP-PEST Regulates Secondary T Cell Responsesrescue effected by the pharmacological inhibitor, in comparison
to the Pyk2 siRNAs, was due to a more complete inhibition of
Pyk2.
Third, we examined the effect of lack of Fyn, the PTK required
for TCR-triggered tyrosine phosphorylation of Pyk2 (Qian et al.,
1997), by breeding PTP-PEST-deficient mice with Fyn/ mice
(Figure 6C,D; Figure S6C). Fyn has been shown to promote
T cell anergy in some systems (Utting et al., 2001; Davidson
et al., 2007), thus potentially opposing the role of PTP-PEST in
this process. Ptpn12/Fyn/ T cells lacked both PTP-PEST
and Fyn (Figure S6C). They exhibited a marked correction
of the elevated Pyk2 tyrosine phosphorylation observed in
Ptpn12/ T cells and, in keeping with the role of Fyn in TCR
signaling, a decrease in TCR-triggered protein tyrosine phos-
phorylation (Figure 6C). More importantly, they showed a mark-
edly reduced sensitivity to anergy (Figure 6D).
Thus, PTP-PEST deficiency enhanced the susceptibility of
T cells to anergy-like states at least in part by causing a deregu-
lation of Pyk2. Lack of Fyn corrected the enhanced Pyk2 tyrosine
phosphorylation and anergy induction in Ptpn12/ T cells, sug-
gesting that PTP-PEST, Pyk2, and Fyn are part of a common
pathway involved in anergy regulation.PTP-PEST-Deficient Mice Are Less Susceptible
to a T Cell-Dependent Immunopathology
The decrease in secondary T cell responses seen in PTP-PEST-
deficient mice suggested that these mice might be less suscep-
tible to certain autoimmune diseases. To address this issue, we
examined their susceptibility to experimental autoimmune
encephalomyelitis (EAE), a model for multiple sclerosis (Figure 7;
Figure S7) (Zhong et al., 2002). In this model, activated CD4+
T cells (T helper 1 [Th1] and Th17 cells) are generated in periph-
eral lymphoid organs after immunization with a MOG peptide
(MOG35-55). MOG-specific T cells then migrate to the central
nervous system (CNS), where they are reactivated by endoge-
nous MOG and cause neurological damage.
Compared to control mice, PTP-PEST-deficient mice were
much less susceptible to EAE (Figure 7A). Both disease fre-
quency and disease severity were lower. This reduction was
not due to a defect in the initial immune response to MOG, given
that PTP-PEST-deficient mice did not exhibit a marked defect in
the production of MOG antibodies (Figure 7B). To verify that the
reduced susceptibility to EAE was not simply due to a defect in
migration of Ptpn12/ T cells through the blood-brain barrier,
we tested secondary MOG-specific CD4+ T cell responses inImmunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc. 175
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Figure 7. Diminished Sensitivity to Experimental Autoimmune Encephalomyelitis in PTP-PEST-Deficient Mice
(A) Mice (n = 7–9 in each group) from the indicated strains were immunized with myelin oligodendrocyte (MOG) peptide 35-55 in adjuvant. After an additional
treatment with pertussis toxin, mice were observed daily for neurological deficits as detailed in the Experimental Procedures. The mean values of the clinical
scores for the different groups of mice are shown. A representative of four experiments is shown.
(B) MOG-specific immunoglobulins (Ig) were detected in the serum of immunized mice (day 40) by ELISA. Symbols represent individual mice. Average values are
shown as horizontal bars. In all cases, p values were nonsignificant (>0.05). A representative of two experiments is shown.
(C) Six weeks after MOG immunization, CD4+ T cells were purified from spleen and restimulated with MOG peptide plus splenocytes. Two mice from each group
are depicted. After 4–5 days, proliferation was determined bymeasuring thymidine incorporation, whereas cytokine secretion was assessed by ELISA. Standard
deviations of triplicates are shown. A representative of five experiments is shown. See also Figure S7.
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PTP-PEST Regulates Secondary T Cell Responsesperipheral lymphoid tissues, by using the in vitro restimulation
assay (Figure 7C). Ptpn12/ splenic T cells exhibited a severely
compromised ability to proliferate and secrete cytokines in
response to MOG restimulation. In contrast, responsiveness to
P+I was normal (Figure S7). Therefore, PTP-PEST deficiency
reduced the susceptibility to EAE, and this effect correlated
with a systemic deficit in secondary T cell responses.
DISCUSSION
Our studies revealed that loss of PTP-PEST, like that of LYP
(Hasegawaet al., 2004), hadnoappreciable impact on thymocyte
development, T cell differentiation, and primary T cell responses.
The lack of a marked effect of PTP-PEST deficiency on primary
T cell responses was in contrast to the results of earlier overex-
pression studies, which suggested a strong inhibitory role of176 Immunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc.PTP-PEST during T cell activation (Badour et al., 2004; Arimura
et al., 2008). Possibly, the inhibitory effect of PTP-PEST seen in
these previous studies was due to nonphysiological conse-
quences of overexpression. Alternatively, the remaining PTP-
PEST expression (<5% of control) in our Ptpn12/ T cells was
perhaps sufficient to offset any alterations of primary responses.
In contrast to primary T cell responses, however, PTP-PEST
deficiency had a prominent impact on secondary responses.
Previously activated Ptpn12/ CD4+ T cells expressing a trans-
genic TCR exhibited a decrease in cytokine secretion and pro-
liferation upon restimulation in vitro. Similarly, after immunization
of PTP-PEST-deficient mice with OVA and adjuvant, T cells
demonstrated severely reduced thymidine incorporation and
cytokine release when restimulated with OVA in vitro. There was
no evidence that the defect in responsiveness of Ptpn12/
T cells was caused by augmented Treg cell numbers or activity.
Immunity
PTP-PEST Regulates Secondary T Cell ResponsesIn some ways, the decreased responsiveness of Ptpn12/
T cells to secondary stimulation was reminiscent of anergy.
In support of this similarity, Ptpn12/ T cells were also more
prone to develop anergy-like states. Combined with the results
outlined above, this finding implied that PTP-PEST deficiency
was compromising the ability of activated T cells to respond to
repeated stimulation. This phenotype is diametrically opposed
to that of LYP deficiency, which augments the responsiveness
of previously activated T cells (Hasegawa et al., 2004; Cloutier
and Veillette, 1999; Gjorloff-Wingren et al., 1999).
Ptpn12/ T cells exhibited an increase in tyrosine phosphor-
ylation of Pyk2, but not of other proteins including known PTP-
PEST substrates. Coupled with our finding that PTP-PEST was
able to dephosphorylate Pyk2 in vitro, these data established
that Pyk2 was a direct substrate of PTP-PEST in T cells. PTP-
PEST has previously been shown to interact with Pyk2 by way
of the adaptor paxillin (Jamieson et al., 2005; Shen et al., 1998;
Lyons et al., 2001; Davidson and Veillette, 2001). To ascertain
whether Pyk2 deregulation explained the abnormal responsive-
ness of Ptpn12/ T cells, we tested the influence of Pyk2 inhibi-
tion on the susceptibility to anergy-like states. Expression of
Pyk2-specific siRNAs or treatment of T cells with a Pyk2 inhibitor
was efficient at preventing anergy. These protective effects were
observed not only in Ptpn12/, but also in normal T cells. More-
over, removal of Fyn, the PTK that phosphorylates Pyk2 in
T cells, corrected the augmented anergy susceptibility of
Ptpn12/ T cells. Hence, deregulated Pyk2 was responsible
at least in part for the increased propensity of Ptpn12/
T cells to become anergized.
WhereasPtpn12/ T cells exhibited normal activation of most
TCR-regulated signals other than Pyk2, they had increased
baseline activity of Rac1, coupled to decreased TCR-triggered
activation of Rac1. Because Rac1 is a downstream effector
of Pyk2 (Gismondi et al., 2003), deregulation of Rac1 was prob-
ably consequential to altered Pyk2 function. In agreement with
the involvement of PTP-PEST, Pyk2 and Rac1 in adhesion,
Ptpn12/ T cells also had altered adhesive properties. Although
they had no defect in the ability to adhere to antigen-presenting
B cells, they had a severe deficiency in the ability to form homo-
typic aggregates during T cell activation. T cell homoaggregates
promote T cell activation and are highly dependent on LFA-1-
ICAM-1 interactions (Sabatos et al., 2008). Consistently, we
found that LFA-1 on Ptpn12/ T cells had a reduced ability to
bind soluble ICAM-1, suggesting that the capacity of LFA-1 on
one T cell to bind ICAM-1 on another T cell might be reduced.
Importantly, addition of exogenous IL-2 or control T cells
restored thymidine incorporation and cytokine production by
Ptpn12/ T cells. Therefore, PTP-PEST may promote sec-
ondary T cell responses by enhancing LFA-1-dependent T cell
homoaggregate formation, possibly by controlling Pyk2 and
Rac1. As suggested (Sabatos et al., 2008), this could in turn favor
exchanges of IL-2 between aggregated cells, thereby augment-
ing T cell proliferation and effector responses. Whether or not
a similar mechanism is involved in protecting against anergy
remains to be examined.
The finding that PTP-PEST deficiency compromised the
responsiveness of previously activated, but not of naive, T cells
wassurprising. Thedeleterious influenceofPTP-PESTdeficiency
may necessitate changes in another cellular protein, perhapsimplicated inPyk2-mediated functions, that occur onlyafter a first
round of T cell activation. Alternatively, the activation-promoting
effect of T cell homoaggregation may occur primarily during
secondary T cell activation. Although the function of LYP in
T cells is qualitatively opposite to that of PTP-PEST, a related
situation exists for LYP. LYP-deficient mice exhibit altered
secondary, but not primary, T cell responses (Hasegawa et al.,
2004; Cloutier and Veillette, 1999; Gjorloff-Wingren et al., 1999).
T cell anergy and anergy-like states are complex processes
that can be triggered in a variety of experimental settings (Choi
and Schwartz, 2007). They have been linked to a range of sig-
naling abnormalities, ranging from a global decrease in TCR-trig-
gered protein tyrosine phosphorylation to a more limited effect
on Erk activation. It is believed that anergy and anergy-like states
are the result of an imbalance in T cell signaling, in which TCR
signaling is not accompanied by proportional signaling through
costimulatory molecules like CD28. The findings that PTP-
PEST deficiency predisposed T cells to anergy-like states and
that inhibition of Pyk2, a PTP-PEST substrate, prevented
anergy-like states provided compelling evidence that PTP-
PEST and Pyk2 are also involved in the regulation of anergy.
Interestingly, though, this activity of PTP-PEST and Pyk2
appeared to be independent of classical anergy mechanisms,
given that activation of NFAT and AP-1 was not affected in
Ptpn12/ T cells. Therefore, PTP-PEST and Pyk2 may be impli-
cated in an alternative anergy-regulating mechanism. This
mechanism may also involve Fyn, given that elimination of Fyn
alleviated the increased Pyk2 tyrosine phosphorylation and
the enhanced sensitivity to anergy-like states observed in
Ptpn12/ T cells. Therefore, PTP-PEST, Pyk2 and Fyn may be
part of a common pathway that influences anergy induction,
independently of deregulation of NFAT and AP-1. A recent report
also linked Pyk2 to an NFAT-AP-1-independent mechanism of
inhibition in macrophages (Wang et al., 2010).
Mice lacking PTP-PEST in T cells were much more resistant to
EAE, a CD4+ T cell-mediated immunopathology. This defect
correlated with a reduction of secondary T cell responses to the
immunizing antigen in in vitro restimulation assays and, thus,
was likely due to decreased reactivation in the CNS of MOG-
specific T cells generated in the periphery. Given the role of
PTP-PEST in migration in other cell types (Larsen et al., 2003), it
is possible that a defect in T cell migration across the blood-brain
barrier also participated in this phenotype. Although future studies
arewarranted to address the role of PTP-PEST in T cell migration,
alterations of T cell migration were unlikely to explain the
decreased sensitivity of PTP-PEST-deficient mice to EAE consid-
ering that the responsiveness of splenic T cells toMOG restimula-
tionwasalsoseverelycompromised.Therefore, thedefect inTcell
responsiveness was systemic rather than restricted to the CNS.
In summary, our data showed that PTP-PEST deficiency in
T cells resulted in compromised secondary responses,
enhanced susceptibility to anergy-like states, and diminished
vulnerability to autoimmunity. Consequently, PTP-PEST carries
out a critical and unique function in T cells, further illustrating
the important role of PTPs in T cell regulation. This function is dia-
metrically opposite to that of LYP (Hasegawa et al., 2004; Clout-
ier and Veillette, 1999; Gjorloff-Wingren et al., 1999) and seems
to be due to the ability of PTP-PEST to regulate Pyk2, a Fyn sub-
strate. Our results also suggested that modulation of PTP-PESTImmunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc. 177
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diseases. The finding that PTP-PEST deficiency diminished the
susceptibility to EAE raised the possibility that inhibition of
PTP-PEST or PTP-PEST-regulated pathways may help treat
multiple sclerosis and other autoimmune diseases.
EXPERIMENTAL PROCEDURES
Mice
The conditional allele of Ptpn12 was generated as described in Supplemental
Experimental Procedures. Ptpn12fl/+ mice were crossed with C57BL/6 mice
for at least eight generations and bred with transgenic mice expressing the
Cre recombinase under the control of the Cd4 or Lck promoter (from Taconic,
Hudson, NY). In some experiments, mice were crossed with class II MHC-
restricted PCC-specific TCR transgenic mice AND or class II MHC-restricted
OVA-specific TCR transgenic mice OT-II (obtained from Taconic) (Barnden
et al., 1998; Kaye et al., 1989). C57BL/6mice were obtained fromHarlan Labo-
ratories (Chicago, IL), whereas B10.BR mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). All animal experimentation was approved by the
IRCM Animal Care Committee and done in accordance with the regulations of
the Canadian Council for Animal Care.
T Cell Activation
For generating previously activated T cells, purified CD4+ T cells were stimu-
lated with plate-bound anti-CD3 mAb 145-2C11 (3 mg/ml) and soluble anti-
CD28 mAb 37-51 (1 mg/ml) for 2 days and then expanded for 3 days in IL-2
(50 U/ml)-containingmedium. For activation, freshly isolated or previously acti-
vated T cells were stimulated for 48 hr with plate-coated anti-CD3 (1–10 mg/ml),
with or without soluble anti-CD28 (1 mg/ml). For TCR AND mice, CD4+ T cells
were stimulated for 6 days with the PCC peptide 88-104 (0.1–10 mM), in the
presence of irradiated splenocytes from B10.BR mice. For TCR OT-II mice,
CD4+ T cells were stimulated for 2 days with the OVA peptide 323-339
(0.04–25 mM), in the presence of irradiated splenocytes from C57BL/6 mice.
As control, cells were stimulated with PMA (100 ng/ml) and ionomycin
(1 mM). After stimulation, proliferation was measured by assaying for
[3H]-thymidine incorporation, whereas cytokine production was revealed by
ELISA (R&D Systems, Minneapolis, MN). All assays were done in triplicate.
Immunization with Ovalbumin
Mice were immunized in the foot pad with OVA protein (100 mg in 25 ml of PBS;
Sigma-Aldrich, St. Louis, MO) in the presence of an equal volume of complete
Freund adjuvant (CFA; Sigma-Aldrich). After 9 days, CD4+ T cells were isolated
frompopliteal lymph nodes and restimulated in vitro for 4–5 days in the presence
of OVA (50–200 mg/ml) and irradiated splenocytes, or for 2 days with P+I. Prolif-
eration and cytokine production were determined. OVA-specific CD4+ T cells
were numerated by staining with phycoerythrin (PE)-labeled class II MHC I-A(b)
tetramers loadedwithOVApeptide323-339oran irrelevantpeptide (humanclass
II-associated invariant chain peptide 103-117) (provided by the NIH Tetramer
Facility, Atlanta, GA). Alternatively, T cells were stimulated for 5 hr with PMA
(50 ng/ml) and ionomycin (800 ng/ml), and IFN-g production was assessed by
intracellular staining, in accordance with the protocol of the manufacturer (BD
Biosciences, Mississauga, ON, Canada). For evaluating suppressor activity,
CD4+ T cells from OVA-immunized PTP-PEST-deficient mice were added to
those fromOVA-immunized control mice at the indicated ratios, prior to restimu-
lation with OVA and irradiated splenocytes. Production of OVA antibodies was
determined by ELISA as detailed in Supplemental Experimental Procedures.
T Cell-Dependent Antibody Production
Mice (6–12 weeks old) were injected intraperitoneally (i.p.) with TNP(12)-CGG
(100 mg in 100 ml of PBS; from Biosearch Technologies, Novato, CA), in the
presence of an equivalent volume of alum (Pierce, Rockford, IL). TNP anti-
bodies were measured in the serum by ELISA as detailed in the Supplemental
Experimental Procedures.
Anergy
For induction of anergy in vitro with anti-CD3 or ionomycin, CD4+ T cells were
first activated for 48 hr with anti-CD3 and anti-CD28 and then expanded for178 Immunity 33, 167–180, August 27, 2010 ª2010 Elsevier Inc.3 days in IL-2. After this, anergy was induced by treating cells for 16 hr with
plate-bound anti-CD3 (1 mg/ml) or ionomycin (1 mM). For anergy triggered
with anti-CD3, cells were then washed and rested for 30 hr. They were later
restimulated for 48 hr with anti-CD3 (0.037, 0.11, or 0.33 mg/ml) and anti-
CD28 (1 mg/ml). For anergy induced by ionomycin, cells were immediately
restimulated with anti-CD3 plus anti-CD28. Thymidine incorporation and
IL-2 secretion were measured. For induction of anergy in vivo, mice were
injected i.p. with Staphylococcus aureus enterotoxin B (SEB) (Sigma-Aldrich;
100 mg in 100 ml of PBS) or with PBS alone. After 10 days, purified splenic
CD4+ T cells were stimulated for 4.5 days with various concentrations of
SEB (0.37–10 mg/ml), in the presence of irradiated splenocytes. Thymidine
incorporation and IL-2 secretion were measured. The percentage of Vb8.1/
8.2+ cells in purified CD4+ T cells was determined by staining with TCR
Vb8.1/8.2-specific mAb MR5-2.Binding to Soluble ICAM-1
Previously activated CD4+ TCR AND T cells were left unstimulated or stimu-
lated for 30 min at 37C with purified B cells, loaded or not with PCC peptide
(5 mM), or with PMA (50 ng/ml). After washing, cells were incubated for 30 min
at room temperature with mouse ICAM-1/Fc chimera (R&D Systems, Minne-
apolis, MN) prelabeled with Alexa Fluor 647 (Molecular Probes, Eugene,
OR). Cells were washed and ICAM-1 binding was evaluated by flow cytometry.
Alexa Fluor 647-labeled human IgG1 was used as isotype control.Pyk2 Inhibition
For downregulation of Pyk2 expression with siRNA, previously activated
T cells were infected with the retroviral vector pSUPER.retro.neo+gfp
(OligoEngine, Seattle, WA) containing the sequences detailed in Supplemental
Experimental Procedures. Infected cells were purified by sorting GFP-positive
cells. After 1–2 days, they were processed for biochemical studies or anergy
induction with anti-CD3.EAE
Mice were injected subcutaneously with 200 ml of an emulsion containing
200 mg of MOG peptide 35-55 in CFA plus 300 mg ofMycobacterium tubercu-
losis H37Ra (Difco Laboratories, Detroit, MI). 24 and 72 hr after the immuniza-
tion, mice were also injected i.p. with 300 ng of pertussis toxin in 0.5 ml of PBS.
They were then observed daily and scored for neurological deficits as follows:
0, no clinical signs; 1, loss of tail tonicity; 2, flaccid tail; 3, hind leg paralysis; 4,
hind leg paralysis with hind body paresis; 5, hind and fore leg paralysis; and 6,
death. After 6 weeks, CD4+ T cells were purified from spleen and restimulated
in vitro with various concentrations of MOG peptide plus irradiated spleno-
cytes, or with P+I, as detailed above for OVA immunization. Production of
MOG antibodies was also measured.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
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